Where I see patients (1)
Selected research
-
Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas.
Journal of neuro-oncology
-
Prospective genomically-guided identification of 'early/evolving' and 'undersampled' IDH-wildtype glioblastoma leads to improved clinical outcomes.
Neuro-oncology
-
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas.
The Journal of clinical investigation
Clinical trials
Hyperpolarized Imaging in Diagnosing Participants With Glioma
Adverse events will be monitored from just before investigational medicinal product (IMP) administration until the end of study participation. Vital signs (blood pressure and heart rate only) will be recorded at baseline and 30 mi...
Recruiting
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
Safety evaluation for endpoint will include monitoring for the occurrence of treatment-emergent adverse events (AEs). Reported toxicities will be graded using the National Cancer Institute (NCI) Common Terminology (Toxicity) Crite...
Recruiting
Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
Patients will be monitored for the occurrence of AEs that occur during the course of study participation. AE monitoring occurs on each day of hyperpolarized 13C pyruvate administration and until 7 days after administration. Seriou...
Recruiting
Contact me
- Request appointment
- Refer a patient
- (415) 353-2966